Dublin, May 05, 2021 (GLOBE NEWSWIRE) -- The "Global CFTR Modulators Market Opportunity, Dosage, Price & Clinical Trials Insight 2026" report has been added to ResearchAndMarkets.com's offering.

Please provide your email address to receive an email when new articles are posted on . Patients from minority racial and ethnic groups with cystic fibrosis are less likely to be eligible for cystic ...

KB407’s positive set of results presented at ATS 2026 follows a set of similar positive results that were announced for the ...

Sionna Therapeutics, Inc. has announced the presentation of promising preclinical data at the 48th European Cystic Fibrosis Conference in Milan, showing that its nucleotide-binding domain 1 (NBD1) ...

Please provide your email address to receive an email when new articles are posted on . Triple therapy improved lung function, BMI and other factors. Patients naïve to cystic fibrosis transmembrane ...

Children ages two to five who have the most common form of cystic fibrosis (CF), caused by two copies of the F508 gene mutation, have not had any modulator treatments available to them until recently.

A recent retrospective study published in CHEST evaluated the effects of cystic fibrosis transmembrane conductance regulator (CFTR) modulator use on pregnancy outcomes in individuals with cystic ...

Over the past three decades, meaningful progress has been made in the research and understanding of cystic fibrosis (CF). 1 While thousands of patients were able to benefit from t ...

Sionna Therapeutics, Inc. announced that preclinical data on its novel cystic fibrosis (CF) treatment candidates, SION-451 and SION-719, will be presented at the European Cystic Fibrosis Society’s ...